Your session is about to expire
← Back to Search
Palmitoylethanolamide for Knee Fracture
Study Summary
This trial will study whether the inclusion of PEA (a non-psychoactive cannabis compound) in conjunction with standard post-surgical medications can reduce pain and inflammation while decreasing the number of opioids needed.
- Knee Fracture
- Tibial Fracture
- Fibula Fracture
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this experiment recruiting participants currently?
"According to the data available on clinicaltrials.gov, this medical trial remains open and is actively accepting patients. It was initially posted on April 1st 2022 with a most recent update occurring at the end of March 2021."
What goals has this research endeavor been designed to accomplish?
"This trial's primary goal, to be assessed over a 3 month period of time, is to assess post-surgical opioid use through questionnaires. Secondary outcomes include Post-Surgical Complications, Pain Interference (measured via PROMIS) and Average Pain Intereference (measured via BPI). Raw scores are converted into T-scores with means of 50 and standard deviations of 10."
How many individuals have been accepted to participate in this research trial?
"Affirmative, clinicaltrials.gov's records reflect that this research project, first published on April 1st 2022 is still recruiting participants. 50 individuals are needed to be enrolled at 2 separate medical facilities."
Is Palmitoylethanolamide safe to consume, and if so, what is the recommended dosage?
"Our team evaluated the safety of palmitoylethanolamide to be a 2 since it is currently in phase two; thus far, there are studies verifying its security but not yet any evidence demonstrating efficacy."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger